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ABSTRACT : Cholesterol fed mice were administered powdered  myrobalan, the fruit of Terminalia chebula, to 
evaluate its antiatherogenic activity. Male mice were fed a diet containing 1% cholesterol with or without myrobalan 
for 100 days. The cholesterol containing diet fed to mice caused increased food intake, body weight, serum   
cholesterol, triglyceride, thickening of the walls of aorta and shrinkage in its lumen (group2) . The oral 
administration of myrobalan to mice on atherogenic diet successfully reversed these effect (group 3 ). However, the 
food intake was observed to be high as compared to the control animals. Control animals (group 1) received only the 
vehicle. The results suggest that myrobalan has hypocholesterolemic  effect in animals fed with atherogenic diet.
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INTRODUCTION 
 
Myrobalan, the fruit of Terminalia chebula 
(Combretaceae) was administered orally to 
mice in order to assess its 
hypocholesterolemic action.  It has been 
reported that myrobalan has a curative role 
in heart diseases and in obesity in humans 1-
2.  As direct relationship exists between the 
serum cholesterol and cardiovascular 
diseases  3, it is of interest to find medicinal 
plants and their products which may be used 
in lowering serum cholesterol4.  However, 
experimental evidence for the 
hypocholesterolemic action of myrobalan is 
limited. Therefore, in the present study, the 
hypocholesterolemic action of myrobalan 
was evaluated in cholesterol fed mice.  
 
EXPERIMENTAL DESIGN  
 
Six months old male swiss albino isogenic 
mice were obtained from The Biological 
Production Division, Government 
Veterinary College, MHOW (M.P.) Mice 
were housed in polypropylene cages with 
free access to drinking water and food.  The 
feed consisted of 36.50% maize, 36.50% 
jowar, 18.50% wheat, 7.50% gram and 1% 
NaC1.  
 
The fruits of myrobalan were purchased 
from local market and were gently baked 
and ground to fine powder.  The aqueous 
suspension of powdered myrobalan was 
prepared and 0.1ml was administered orally 
to mice at a calculated dose of 128 mg/kg 
body weight/day (3.2mg/25gm mouse/day). 
Human dose is 3-9gm/day for an adult of 
70kg body weight, therefore dose ranges 
from 42.85mg/kg to 128.57mg/kg.  This is 
the basis of selecting the present dose which 
is well within recommended limits.   
Cholesterol (CDH, New Delhi) 1% was 
mixed along with the feed. 
 
Each group of animals comprised of 6 mice.  
Group 1 served as control which was given 
only vehicle (0.1 ml distilled water 
orally/day/mouse.) Another group of mice 
was fed 1 % cholesterol w/w for 100 days 
without or with myrobalan (group 2 and 3 
respectively). 
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large group of mice were recorded on zero 
day i.e. on the onset day of experimentation 
which were used as base line for 
comparison, hence initial values are same in 
all groups.  This large group of mice were 
randomly divided in to above mentioned 
three subgroups (Gr.I, Gr.II & Gr.III). 
 
The mice were weighed on zero days i.e. at 
the start (initial value) and at the end of the 
experiment (final value).  Food intake was 
determined by weighing the leftover food.   
After an overnight fast, the animals were 
anesthetized and blood was drawn by heart 
puncture.  Serum cholesterol and 
triglycerides were determined using the kit 
method of Accurex Biomedical Pvt. Ltd., 
Thane, India.  Experiments were   performed 
in duplicate.  Sections of aorta, 5 mm thick, 
were fixed using Bouin’s solution and 
stained using hematoxlyin eosin.  The 
percentage area of wall and lumen of aorta 
was measured using camera lucida 
drawings.  Mean values of wall and lumen 
of aorta were obtained from five sections.  
 
The statistical analysis was performed by 
students ‘t’ test and the values  less than 5% 
were considered significant. 
 
RESULTS  
 
Cholesterol feeding to mice (group 2) 
resulted in an increased body weight as 
compared to controls (table 1, group 1). 
Myrobalan administration to cholesterol fed 
mice (group 3) showed decrease in body 
weight as compared to cholesterol fed 
animals (group 2) 
 
Cholesterol feeding (group 2) to mice 
caused higher food intake as compared to 
control (group1)   animals. Myrobalan 
administration to cholesterol fed mice 
(group 3) also resulted in higher food intake 
than control. 
 
Cholesterol feeding to mice (group 2) 
resulted in an increased serum cholesterol, 
serum triglyceride and area of wall of aorta 
and decreased lumen in comparison to the 
control (group 1), myrobalan administration 
to cholesterol fed mice (group 3) 
significantly reversed these effects of 
cholesterol feeding  
 
DISCUSSION 
 
The atherogenic diet fed to mice increased 
the food intake, which resulted in the 
increased body weight of the animals. 
Atherodiet elevated serum cholesterol and 
triglyceride levels (Table 1). Myrobalan 
treatment to cholesterol fed animals 
significantly decreased serum cholesterol, 
triglycerides, as well as the body weight. 
However, no significant decrease in food 
intake was      observed in this group (group 
3). 
 
It is probable that the synthesis and 
degradation of cholesterol is altered by 
myrobalan treatment. Myrobalan consists of 
saponins, which have been shown to prevent 
cholesterol absorption   as they interfere 
with the enterohepatic circulation and 
increases its excretion4,5. Myrobalan inducts 
gastric motility and also enhances gastric 
emptying  6 which may contribute to more 
excretion of cholesterol resulting in 
decreased serum cholesterol levels. A herbal 
drug containing T. chebula was observed to 
be effective against CC14- induced 
hepatopathy and hematological changes7. 
Some reports suggest that tannins increased 
faecal bile excretion4 .  As  myrobalan 
possesses  both  saponins and tannins, it is 
possible that absorption of cholesterol 
decreased with increase in cholestrol 
pages 11 - 15excretion through bile, in          myrobalan  
fed animals  (group 3 ). 
 
The leaves of T. chebula were found to exert 
hypolipidemic action through  inhibition of 
cholesterol biosynthesis and  increased 
faecal bile excretion8.It is also observed that 
T.chebula enhanced lecithin : cholesterol   
acyl transferase (LCAT) activity8, which  is 
important in the elimination of cholesterol 
ester, which diffuses into the core of HDL 
particles. Myrobalan  may thus decrease the 
synthesis of cholesterol and also eliminate it 
through bile or metabolize it to other non- 
harmful components. 
 
Flavanoids have been reported to have 
antihyperlipidemic properties 9,10  Some 
terpenoids were shown to inhibit LPO11 . 
Naturally occuring triterpenoids and some of 
their derivatives are known to have 
hypolipidemic activity12,13.  Antioxidant      
action of T. chebula has also been suggested 
14. The presence of  flavanoids and terpenoids 
in myrobalan may thus lower the serum 
cholesterol and  triglyceride levels in group 
3 animals. 
 
It is concluded that myrobalan lowers serum 
cholesterol and triglyceride levels  probably 
by altering synthesis, degradation and 
eleimination of cholesterol. 
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Table 1 : Effect of Myrobalan on various parameters in mice fed atherogenic diet 
 
Group of Mice  S. 
No. 
Parameters 
1 (Controls)    2 (Atherodiet)  3 (Atherodiet 
+ Myrobalan) 
Initial  25.65 ± 0.46  25.65 ± 0.46  25.65 ± 0.46 
Final  28.12 ± 0.33*  30.48 ± 0.53 *
b  28.32 ± 0.28*
c 
01 Body  Weight  (gm) 
% Change               (9.62)                  (18.83)             (10.40) 
Initial  5.61 ± 0.56  5.61 ± 0.56  5.61 ± 0.56 
Final  7.51 ± 0.47*  9.15 ± 0.55 *b  9.21 ± 0.61 *
a 
02 Food  Intake 
(gm/day/mouse) 
% Change             (33.86)            (63.10)             (64.17) 
Initial  126.05 ± 3.61  126 .05 ± 3.61  126.05 ± 3.61. 
Final  128.96 ± 2.77  178.50 ± 188 *
b  148.77 ± 3.14*
a,c 
03 Serum  Cholesterol 
(mg%) 
% Change             (2.30)             (41.61)                 (18.02) 
Initial  105.61 ± 3.89  105.61 ± 3.89  105.61 ± 3.89 
Final  108.14 ± 3.15  141.11 ± 3.37 *
b  119.44 ± 2.80*
a,c 
04 Serum  Triglyceride 
(mg%) 
% Change            (2.36)               (33.61)              (13.07) 
Initial  15.02 ± 1.48  15.02 ± 1.48  15.02 ± 1.48 
15.11 ± 1.62  27.45 ± 1.08 *
b  19.60 ± 1.13 *
a,c 
Ascending aorta 
Wall  Final 
          (0.59)              (82.75)             (30.49) 
Initial  84.98 ± 1.11  84.98 ± 1.11  84.98 ± 1.11 
84.89 ± 1.01  72.55 ± 1.23 *
b  80.40 ± 1.01 *
a,c 
05 
(% area of ) & 
Lumen  Final 
          (0.10)            (14.62)               (5.38) 
 
Values are mean + SEM of 6 animals. a,b,c are p value (0.05), a,b,c refer to when group 3 was 
compared to group 1, group 2 was compared to group 1 and group 3 was compared to group 2 
respectively. Value in parenthesis indicate % change. 
 
*- Significant difference between initial and final changes when values were comrpared within a 
group only. 
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